Gut microbiota plays a predominant role in affecting hypolipidemic effect of Deacetylated Konjac Glucomannan (Da-KGM)

The mechanism of Da-KGM showed poorer hypolipidemic effect, has not elucidated in previous study. Here, we performed hyperlipidemic hamsters administrated with 6% KGM (Konjac Glucomannan) and Da-KGM respectively to evaluate different underlying mechanisms. Poorer lipid-lowering effect was shown with Da-KGM treatment, and marked changes in relative abundance of Aldercreutzia and Parasutterella were not detected as KGM. Meanwhile, significant alteration of Ileibacterium was observed between KGM and Da-KGM group. Moreover, pathway of primary bile acids synthesis was enriched in cecal metabolites. KGM, not Da-KGM, remarkably increased concentration of Glycocholic acid (GCA) and Ursodeoxycholic acid (UDCA), which were negatively corrected with Ileibacterium. Marked increases in ileal Farnesoid X receptor (FXR) and hepatic Cholesterol 7 alpha-hydroxylase (CYP7A1) were observed in KGM group, along with strong reduction of ileal Multi drug resistance-associated protein2 (MRP2/ABCC2) and hepatic FXR expression, but not in Da-KGM group. There were no obvious changes in serum lipid level and bile acids, as well as gene expression after antibiotic treatment. Our results revealed that different hypolipidemic effects of KGM and Da-KGM might be associated with gut microbiota and bile acids metabolism.

Automated summary

This study found that the hypolipidemic effects of KGM and Da-KGM are different and may be associated with gut microbiota and bile acids metabolism.